Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

E-MTAB-5243

ABSTRACT: Ampliseq transcriptomic array of REF seq. genes in ZEB1 knock out triple negative breast cancer cells

PROVIDER: E-MTAB-5243 | ExpressionAtlas | 2025-01-23

REPOSITORIES: ExpressionAtlas

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	E-MTAB-5243-analysis-methods.tsv	Tabular
	E-MTAB-5243-analytics.tsv	Tabular
	E-MTAB-5243-atlasExperimentSummary.Rdata	Rdata
	E-MTAB-5243-configuration.xml	Xml
	E-MTAB-5243-g2_g1-mvaPlot.png	Other

Items per page:

1 - 5 of 22

Similar Datasets

Ampliseq transcriptomic array of REF seq. genes in ZEB1 knock out triple negative breast cancer cells

Project description:Ampliseq transcriptomic array of REF seq. genes in ZEB1 knock out triple negative breast cancer cells

| PRJEB17976 | ENA

Ampliseq transcriptomic array of REF seq. genes in Snai1 knock out triple negative breast cancer cells

Project description:Ampliseq transcriptomic array of REF seq. genes in Snai1 knock out triple negative breast cancer cells

| PRJEB18008 | ENA

E-MTAB-5244

Project description:Ampliseq transcriptomic array of REF seq. genes in Snai1 knock out triple negative breast cancer cells

2025-01-23 | E-MTAB-5244 | ExpressionAtlas

SMARCA4 loss-of-function induces cisplatin resistance to activate YAP1-dependent epithelial-to-mesenchymal in triple negative breast cancer

Project description:We report transcriptome profiling (RNA-seq) for SMARA4 knock-out to elucidate the association with cisplatin-resistance and SMARCA4 loss-of-function using triple negative breast cancer cell lines.

2021-11-17 | GSE178532 | GEO

Pro-metastatic role of catechol-O-methyl transferase in triple negative breast cancer is demonstrated by modulation of cell migration, invasion and cell cycle progression

Project description:Catechol O-methyl transferase (COMT), a transmembrane protein essential for catechol estrogen detoxification, has been associated with increased migration in triple negative breast cancer (TNBC) in our previous study. Here we studied the role of COMT in TNBC functionally using two clones (B1, D10) of MDA-MB-231 cells with knock-out expression of COMT compared with parental cell line. We performed comparative gene expression analysis using data obtained from RNA-seq of cells with silenced COMT and control cells in biological duplicates.

2025-04-30 | GSE242452 | GEO

Genome-wide mapping of ZNF148 binding sites in MDA-MB-231 cell line

Project description:ChIP-Seq was carried out to map the genome-wide chromatin occupancy of ZNF148 in a basal subtype triple negative breast cancer cell-line, MDA-MB-231.

2022-10-04 | GSE147020 | GEO

FZD7 Plays a Critical Role in Triple Negative Breast Cancer Proliferation

Project description:Breast cancer is genetically and clinically heterogeneous. Triple negative cancer (TNBC) is a subtype of breast cancer usually associated with poor outcome and lack of benefit from target therapy. A pathway analysis in a microarray study was performed using TNBC compared with non-triple negative breast cancer (non-TNBC). Overexpression of several Wnt pathway genes, such as frizzled homolog 7 (FZD7), Low density lipoprotein receptor-related protein 6 (LRP6) and transcription factor 7 (TCF7) has been observed in TNBC. Focus was given to the Wnt pathway receptor, FZD7. To validate its function, inhibition of FZD7 using FZD7shRNA was carried out. Notably decreased cell proliferation, suppressed invasiveness and colony formation in triple negative MDA-MB-231 and BT-20 cells were observed. Mechanism study indicated that these effects occurred through silencing the canonical Wnt signaling pathway, as evidenced by loss of nuclear accumulation of ï?¢-catenin and decreased transcriptional activity of TCF7. In vivo study revealed that FZD7shRNA significantly suppressed the tumor formation in xenotransplation mice due to decrease cell proliferation. Our finding suggests that FZD7 involved canonical Wnt signaling pathway is essential for tumorigenesis of TNBC. Thus, FZD7 may be a biomarker and a potential therapeutic target for triple negative breast cancer. 14 pretreatment non-triple negative breast tumors compare with 5 triple negative breast tumor.

2011-06-01 | E-GEOD-27447 | biostudies-arrayexpress

Ampliseq transcriptomic array of REF seq. genes in ZEB1 knock out triple negative breast cancer cells

Project description:Aim of this study is to unveil the global transcriptomic expression levels upon Knockout of ZEB1 in triple negative breast cancer cells Hs578T.

2018-04-25 | E-MTAB-5243 | biostudies-arrayexpress

Ampliseq transcriptomic array of REF seq. genes in Snai1 knock out triple negative breast cancer cells

Project description:Aim of this study is to unveil the global transcriptomic expression levels upon Knockout of Snai1 in triple negative breast cancer cells Hs578T.

2018-04-25 | E-MTAB-5244 | biostudies-arrayexpress

Gene expression profile at single cell level of 4T1 WT and Mga KO tumors derived on BALB/c mice

Project description:Immune evasion is critical for tumor initiation and progression, as well as determining the efficacy of immunotherapies. Through iterative in vivo CRISPR screens within seven syngeneic tumor models, we not only identified the core immune evasion pathways and context-dependent ones across cancer types but also provided a high-confidence valuable dataset for understanding tumor intrinsic immunomodulators and discovering novel anti-cancer therapeutic targets. With a focus on triple-negative breast cancer (TNBC), we found that Mga knock-out significantly enhances anti-tumor immunity and inhibits the tumor growth of TNBC model. Transcriptomics and single cell-RNA (sc-RNA) seq analyses revealed Mga function through, at least partially, repression of MHC-II genes and related immune responses. Consistently, we observed that low MGA expression in breast cancer patients correlates with a favorable prognosis, particularly in those with active interferon-g signaling. Our findings provide new insights into tumor immune escape and pave the way for further exploration of MGA inhibition for clinical benefits in triple-negative breast cancer.

2024-09-06 | GSE249758 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data